GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 18, Issue 6, 1996, Pages 1057-1064

  Greenberg, P ^a,j   Advani, R ^a   Keating, A ^b   Gulati, S C ^c   Nimer, S ^d   Champlin, R ^d   Karanes, C ^e   Gorin, N C ^f   Powles, R L ^g   Smith, A ^b   Lamborn, K ^h   Cuffie, C ⁱ  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

^f HÔPITAL SAINT ANTOINE   (France)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

BMT; Bone marrow transplantation; GM CSF

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOTRANSPLANTATION; CELL TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; EDEMA; FEMALE; FEVER; HEMATOPOIETIC STEM CELL; HODGKIN DISEASE; HUMAN; HYPOALBUMINEMIA; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELOMA; NEUTROPHIL; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGOR; SIDE EFFECT; SOLID TUMOR; STEM CELL TRANSPLANTATION; STOMATITIS; THROMBOCYTE;

ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LENGTH OF STAY; LIFE TABLES; MALE; MIDDLE AGED; NEUTROPENIA; NEUTROPHILS; RECOMBINANT PROTEINS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 8044220922     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Bortin MM, Horowitz MM. Current status of bone marrow transplantation. In Terasaki PI (ed.). Clinical Transplants 1989. UCLA Tissue Typing Laboratory: Los Angeles, 1989, pp 93-101.
2. Advisory Committee of the International Bone Marrow Transplant Registry. Report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1989; 4: 221-228.
3. Gratwohl A. Bone marrow transplantation activity in Europe 1990. Bone Marrow Transplant 1991; 8: 197-201.
4. Blume KGL. Marrow transplantation. In: Williams WJ, Beutler E, Erslev AJ et al (eds). Hematology (edn 4). McGraw-Hill Inc: New York, 1990, pp 1674-1685.
5. Gorin NC. Autologous bone marrow transplantation in hematological malignancies. Am J Clin Oncol 1991; 16 (Suppl. 1): S5-S14.
6. Frei E III, Antman K, Teicher B et al. Bone marrow autotransplantation for solid tumors - prospects. J Clin Oncol 1989; 7: 515-526.
7. Cheson BD, LaCerna L, Leyland-Jones B et al. Autologous bone marrow transplantation. Ann Intern Med 1989; 110: 51-65.
8. Ferrara JLM, Deeg HJ. Graft-versus-host disease. New Engl J Med 1991; 324: 667-674.
9. Toney JF, Sinnott JT IV, Ivey P et al. Infections in bone marrow transplantation: V. Infect Dis Newslett 1989; 8: 81-83.
10. Meyers JD. Infections in marrow transplant recipients. In: Mandell GL, Douglas RG Jr, Bennett JE (eds). Principles and Practice of Infectious Diseases (edn 3). Churchill Livingstone: New York. 1990, pp 2291-2294.
11. Elias AD, Mazanet R, Wheeler C et al. GM-CSF potentiated peripheral blood progenitor cell (PBPC) collection with or without bone marrow as hematologic support of high-dose chemotherapy: two protocols. Breast Cancer Res Treat 1991; 20: S25-S29.
12. Lieschke GJ, Maher D, Cebon J et al. Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. Ann Intern Med 1989; 110: 357-364.
13. Aglietta M, Piacibello W, Sanavio F et al. Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor. J Clin Invest 1989; 83: 551-557.
14. Steward WP, Scarffe JH, Austin R et al. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) given as daily short infusions - a phase I dose-toxicity study. Br J Cancer 1989; 59: 142-145.
15. Steis RG, Vandermolen LA, Longo DL et al. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial. J Natl Cancer Inst 1990; 82: 697-703.
16. Herrmann F, Ganser A, Lindemann A et al. Stimulation of granulopoiesis in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor: assessment of two routes of administration. J Biol Response Mod 1990; 9: 475-479.
17. Villeval J-L, Duhrsen U, Morstyn G et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on progenitor cells in patients with advanced malignancies. Br J Haematol 1990; 74: 36-44.
18. Socinski MA, Cannistra SA, Elias A et al. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988; i: 1194-1198.
19. Antman KS, Griffin JD, Elias A et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. New Engl J Med 1988; 319: 593-598.
20. Gianni AM, Bregni M, Siena S et al. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 1990; 8: 768-778.
21. Bettelheim P, Valent P, Andreeff M et al. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 1991; 77: 700-711.
22. Jost LM, Pichert G, Stahel RA. Placebo controlled phase I/II study of subcutaneous GM-CSF in patients with germ cell tumors undergoing chemotherapy. Ann Oncol 1990; 1: 439-442.
23. Gasson JC. Molecular physiology of granulocyte-macrophage colony-stimulating factor. Blood 1991; 77: 1131-1145.
24. Link H, Boogaerts M, Carella A et al. A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy and autologous bone marrow transplant for acute lymphoblastic leukemia or malignant lymphoma. Blood 1992; 80: 2188-2195.
25. Brandt SJ, Peters WP, Atwater SK et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. New Engl J Med 1988; 318: 869-876.
26. Nemunaitis J, Singer JW, Buckner CD et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies. Blood 1988; 72: 834-836.
27. Nemunaitis J, Rabinowe SN, Singer JW et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. New Engl J Med 1991; 324: 1773-1778.
28. Devereaux S, Linch DC, Gribben JG et al. GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease. Bone Marrow Transplant 1989; 4: 49-54.
29. Lazarus HM, Andersen J, Chen MG et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for relapsed non-Hodgkin's lymphoma: blood and bone marrow progenitor growth studies: a phase II Eastern Cooperative Oncology Group trial. Blood 1991; 78: 830-837.
30. Advani R, Chao NJ, Horning SJ et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. Ann Intern Med 1992; 116: 183-189.
31. Khiwaja A, Linch DC, Goldstone AM et al. Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma. A British National Lymphoma Investigation double blind, placebo-controlled trial. Br J Haematol 1992; 82: 317-323.
32. Gianni AM, Bregni M, Siena S et al. Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells: a changing role for high-dose chemo-radiotherapy? Hematol Oncol 1989; 7: 139-148.
33. Gianni AM, Tarella C, Siena S et al. Durable and complete hematopoietic reconstitution after autografting of rhGM-CSF exposed peripheral blood progenitor cells. Bone Marrow Transplant 1990; 6: 143-145.
34. Antman K, Elias A, Hunt M et al. GM-CSF potentiated peripheral blood progenitor cell (PBPC) collection and use after high-dose chemotherapy. Blood 1990; 76 (Suppl. 1): 526a (Abstr.).
35. Haas R, Ho AD, Bredthauer U et al. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 1990; 18: 94-98.
36. Kessinger A, Armitage JO. The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 1991; 77: 211-213.
37. Huan SD, Hester J, Spitzer G et al. Influence of mobilized peripheral blood cells on the hematopoietic recovery by autologous marrow and recombinant human granulocyte-macrophage colony-stimulating factor after high-dose cyclophosphamide, etoposide, and cisplatin. Blood 1992; 79: 3388-3393.
38. Shea TC, Mason JR, Storniolo AM et al. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncol 1992; 10: 464-473.
39. Elias AD, Ayash L, Anderson KC et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992; 79: 3036-3044.
40. Bodey GP, Buckley M, Sathe YS et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-340.
41. Gianni AM, Siena S, Bregni M et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; ii: 580-585.
42. Gulati SC, Bennett CL. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med 1992; 116: 177-182.
43. Valtieri M, Santoli D, Caracciolo D et al. Establishment and characterization of an undifferentiated human T leukemia cell line which requires granulocyte-macrophage colony-stimulating factor for growth. J Immunol 1987; 138: 4042-4050.
44. Kupper T, Flood P, Coleman D, Horowitz M. Growth of an interleukin 2/interleukin 4-dependent T cell line induced by granulocyte-macrophage colony-stimulating factor. J Immunol 1987; 138: 4288-4297.
45. Rabinowe SN, Neuberg D, Bierman PJ et al. Long-term follow up of a phase III study of recombinant human GM-CSF after autologous bone marrow transplantation for lymphoid malignancies. Blood 1993; 81: 1903-1908.
46. Klumpp T, Morgan K, Goldberg S et al. G-CSF accelerates neutrophil engraftment following peripheral blood stem cell transplantation: a prospective, randomized trial. J Clin Oncol 1994; 13: 1323-1327.